Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 50%
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cnbc.com — the content belongs to CNBC.
